Archives

CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning

CytoReason Expands Its Reach in Asia_ Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers logo/IT Digest

CytoReason, a leading developer of computational disease models for efficient drug discovery and development, announced the signing of a commercial partnership with Helixrus, a leading Korean company focused on biological big data and multi-omics. The partnership will see Helixrus represent CytoReason’s unique AI platform and professional services in the Korean market.

CytoReason has established itself as a global leader in computational modeling of human diseases. The company’s multidisciplinary team of 65 leading biologists, bioinformaticians and data engineers has developed a technology that enables pharma and biotech companies to speed up drug R&D and bring novel therapies to the patients who most need them.

The alliance will focus on leveraging Helixrus’ deep knowledge of the Korean pharmaceutical market, and extensive network of relationships in Asian markets, to highlight CytoReason’s capabilities in prioritizing new targets, finding biomarkers, profiling combinations, stratifying patients, and other use cases within the drug lifecycle.

CytoReason has existing collaborations with five of the world’s largest pharmaceutical companies, including Pfizer and Sanofi. Its proprietary platform has yielded a range of clinically validated results in multiple diseases.

Also Read: Adaptavist Receives Atlassian Partner of the Year 2021 Cloud…

“We’re thrilled to enter the Korean market with such an important player in South Korea’s pharmaceutical industry,” said David Harel, CEO and Co-founder of CytoReason. “Through this collaboration and others in Asian markets, our goal is to establish our computational disease models and professional services as the gold standard for drug discovery, development and portfolio management.”

“We are very excited to partner with CytoReason as they expand their footprint into Korea,” said Nick Choe, CEO of Helixrus, Inc. “CytoReason offers a unique AI drug discovery platform that already benefits a number of pharmaceutical companies worldwide, and we look forward to working together to improve drug discovery and development in Korea as well.”

About CytoReason

CytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies and uses it to simulate human diseases